Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AZD3632 · 1 trial · 3 indications
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed.
Safety and tolerability of AZD3632 monotherapy in participants with advanced haematologic malignancies will be assessed. Adverse events will be defined as treatment-emergent if they have an onset or worsen (by investigator report of a change in intensity) during the study treatment or the safety follow-up period but prior to any subsequent cancer therapy.
| Arm | Type | Description |
|---|---|---|
| Module 1: AZD3632 dose 1 | EXPERIMENTAL | Participants will receive AZD3632 (dose 1) through the treatment period. |
| Module 1: AZD3632 dose 2 | EXPERIMENTAL | Participants will receive AZD3632 (dose 2) through the treatment period. |
| Module 1: AZD3632 dose 3 | EXPERIMENTAL | Participants will receive AZD3632 (dose 3) through the treatment period. |
| Module 1: AZD3632 dose 4 | EXPERIMENTAL | Participants will receive AZD3632 (dose 4) through the treatment period. |
| Module 1: AZD3632 dose 5 | EXPERIMENTAL | Participants will receive AZD3632 (dose 5) through the treatment period. |
| Module 1: AZD3632 dose 6 | EXPERIMENTAL | Participants will receive AZD3632 (dose 6) through the treatment period. |
| Module 2: AZD3632 + posaconazole | EXPERIMENTAL | Participants will receive AZD3632 alone, then will receive AZD3632 in combination with posaconazole through treatment period. |
| Name | Type | Description |
|---|---|---|
| AZD3632 | DRUG | AZD3632 will be administered orally. |
| Posaconazole | DRUG | Posaconazole will be administered orally. |
Key Inclusion Criteria: Core criteria: * Adequate organ function. * Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Module 1: * Advanced haematologic malignan...
AZD3632 is an investigational small molecule being developed for the treatment of acute lymphoblastic leukaemia. It is also being studied in acute myeloid leukaemia and higher-risk myelodysplastic syndromes. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
AZD3632 is being developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical trials to evaluate the safety and efficacy of this investigational drug in patients with advanced haematologic malignancies.
AZD3632 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety, tolerability, and preliminary efficacy.
AZD3632 is being evaluated in a Phase 1 clinical trial registered as NCT07155226. This trial is studying AZD3632 as a monotherapy or in combination with other anticancer agents in participants with advanced haematologic malignancies, including acute lymphoblastic leukaemia, acute myeloid leukaemia, and higher-risk myelodysplastic syndromes. The trial is currently recruiting participants.
AZD3632 is a small molecule being studied for its potential to treat certain haematologic malignancies. The ongoing clinical trial is enrolling patients with KMT2Ar, NPM1m, or other genotypes associated with HOX overexpression, suggesting the drug may target pathways related to these genetic alterations. However, the specific molecular mechanism of action has not been disclosed.